PD‐L1/TIGIT bispecific antibody showed survival advantage in animal model

PD‐L1/TIGIT bispecific antibody showed survival advantage in animal model

Bibliographic Details
Main Authors:	Songlin Mu, Zhijuan Liang, Yongmei Wang, Wendi Chu, Yi‐Li Chen, Qi Wang, Guifeng Wang, Chunhe Wang
Format:	Article
Language:	English
Published:	Wiley 2022-05-01
Series:	Clinical and Translational Medicine
Online Access:	https://doi.org/10.1002/ctm2.754

Similar Items

Development of a bispecific antibody targeting PD-L1 and TIGIT with optimal cytotoxicity
by: Zhenwei Zhong, et al.
Published: (2022-10-01)

HER2/PD1 bispecific antibody in IgG4 subclass with superior anti‐tumour activities
by: Wendi Chu, et al.
Published: (2022-04-01)

473 LAE113, a novel TIGIT/PVRIG bispecific antibody for the treatment of cancer
by: Yan Chen, et al.
Published: (2023-11-01)

A novel anti-LAG-3/TIGIT bispecific antibody exhibits potent anti-tumor efficacy in mouse models as monotherapy or in combination with PD-1 antibody
by: Tongcheng Dai, et al.
Published: (2024-05-01)

Dual-target Bridging ELISA for Bispecific Antibodies
by: Min Pei, et al.
Published: (2022-10-01)

Comparison of “framework Shuffling” and “CDR Grafting” in humanization of a PD-1 murine antibody
by: Yongmei Wang, et al.
Published: (2024-07-01)

Co-inhibition of TIGIT and PD-1/PD-L1 in Cancer Immunotherapy: Mechanisms and Clinical Trials
by: Xianjing Chu, et al.
Published: (2023-06-01)

Correction: Co-inhibition of TIGIT and PD-1/PD-L1 in Cancer Immunotherapy: Mechanisms and Clinical Trials
by: Xianjing Chu, et al.
Published: (2023-06-01)

Prodrug-based bispecific antibodies for cancer therapy: advances and future directions
by: Zhijuan Ai, et al.
Published: (2025-01-01)

Bispecific antibody targeting TGF-β and PD-L1 for synergistic cancer immunotherapy
by: Tianye Li, et al.
Published: (2023-07-01)

TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM
by: Alice L. Hung, et al.
Published: (2018-08-01)

Circulating TIGIT±PD1+TPH, TIGIT ± PD1+TFH cells are elevated and their predicting role in systemic lupus erythematosus
by: Qing Luo, et al.
Published: (2024-03-01)

492 Development of a tri-specific antibody targeting PD-1/CTLA-4/TIGIT
by: Fei Peng, et al.
Published: (2023-11-01)

TIGIT+Tfh show poor B-helper function and negatively correlate with SARS-CoV-2 antibody titre
by: Natalie M. Edner, et al.
Published: (2024-05-01)

The enhanced antitumor activity of bispecific antibody targeting PD-1/PD-L1 signaling
by: Tianye Li, et al.
Published: (2024-03-01)

1383 Preclinical characterization of D3L-002, a novel cancer immunotherapy bispecific antibody that elicits potent anti-tumor efficacy via co-blocking TIGIT and PVRIG
by: Jia Wang, et al.
Published: (2023-11-01)

PD-L1/LAG-3 bispecific antibody enhances tumor-specific immunity
by: Haiping Jiang, et al.
Published: (2021-01-01)

Polymeric PD1/PDL1 bispecific antibody enhances immune checkpoint blockade therapy
by: Fuxin Xue, et al.
Published: (2024-10-01)

PVR/TIGIT and PD-L1/PD-1 expression predicts survival and enlightens combined immunotherapy in lung squamous cell carcinoma
by: Zhenlin Yang, et al.
Published: (2022-10-01)

Production of native bispecific antibodies in rabbits.
by: Wei Wang, et al.
Published: (2010-01-01)

A bispecific anti-PD-1 and PD-L1 antibody induces PD-1 cleavage and provides enhanced anti-tumor activity
by: Diana I. Albu, et al.
Published: (2024-12-01)

ACE2-targeting monoclonal antibody as potent and broad-spectrum coronavirus blocker
by: Yuning Chen, et al.
Published: (2021-08-01)

Biophysical characterization of PVR family interactions and therapeutic antibody recognition to TIGIT
by: SJ J. Diong, et al.
Published: (2023-12-01)

A reporter gene assay for determining the biological activity of therapeutic antibodies targeting TIGIT
by: Zhihao Fu, et al.
Published: (2021-12-01)

A Novel Bispecific Antibody Targeting PD-L1 and VEGF With Combined Anti-Tumor Activities
by: Xiaopei Cui, et al.
Published: (2021-12-01)

Differential impact of genetic deletion of TIGIT or PD-1 on melanoma-specific T-lymphocytes
by: Gwenann Cadiou, et al.
Published: (2024-12-01)

Bispecific antibody drug conjugates: Making 1+1>2
by: Yilin Gu, et al.
Published: (2024-05-01)

Comparative Characterization of Different Molecular Formats of Bispecific Antibodies Targeting EGFR and PD-L1
by: Nishant Mohan, et al.
Published: (2022-06-01)

PD-1/LAG-3 bispecific antibody potentiates T cell activation and increases antitumor efficacy
by: Ning Shi, et al.
Published: (2022-11-01)

The Ratio of CD226 and TIGIT Expression in Tfh and PD-1+ICOS+Tfh Cells Are Potential Biomarkers for Chronic Antibody-Mediated Rejection in Kidney Transplantation
by: Ji-wen Fan, et al.
Published: (2022-01-01)

Cadonilimab, a tetravalent PD-1/CTLA-4 bispecific antibody with trans-binding and enhanced target binding avidity
by: Xinghua Pang, et al.
Published: (2023-12-01)

Bispecific antibodies in follicular lymphoma
by: Imran A. Nizamuddin, et al.
Published: (2024-10-01)

Bispecific antibodies for viral immunotherapy
by: Elisabeth K. Nyakatura, et al.
Published: (2017-04-01)

Bispecific antibodies in cancer immunotherapy
by: Eva Dahlén, et al.
Published: (2018-02-01)

Synergistic efficacy of simultaneous anti-TGF-β/VEGF bispecific antibody and PD-1 blockade in cancer therapy
by: Mengke Niu, et al.
Published: (2023-08-01)

Novel bispecific aptamer targeting PD-1 and nucleolin for cancer immunotherapy
by: Junjun Fu, et al.
Published: (2023-03-01)

A bispecific antibody based assay shows potential for detecting tuberculosis in resource constrained laboratory settings.
by: Susmita Sarkar, et al.
Published: (2012-01-01)

Addition of anti-TIM3 or anti-TIGIT Antibodies to anti-PD1 Blockade Augments Human T cell Adoptive Cell Transfer
by: Marina Martinez, et al.
Published: (2021-01-01)

485 TIGIT/PVRIG humanized mice-an idea model for studying anti-PVRIG antibodies
by: Xiang Gao, et al.
Published: (2023-11-01)

TIGIT acts as an immune checkpoint upon inhibition of PD1 signaling in autoimmune diabetes
by: Prerak Trivedi, et al.
Published: (2024-03-01)